Corporate News: Circle (CIRC) Market Performance and Corporate Developments
Trading Performance
- Closing Price (08:04 PM CET, 20 Oct 2026): USD 0.38
- 24‑hour Change: Up 12.25 %
- Volume Traded (Last 24 h): USD 358.5 k
- Shares Outstanding: 114.4 million
- Market Capitalisation: USD 34.5 million
- Simple Moving Average (200 days): USD 1.69
- 52‑Week High: USD 4.56 (16 Mar 2026)
- 52‑Week Low: USD 0.29 (19 Oct 2026)
Since the close of the previous month, Circle shares have declined 20.05 %.
Corporate Action – Takeover Proposal
- Offeror: Circle8 Group Inc.
- Target: SThree plc
- Offer Period: 9 Sep 2026 – 21 Oct 2026 (deadline to announce intent to bid)
- Status: Proposal remains open; no additional disclosures or changes reported in the Disclosure Table for Circle8.
- Regulatory Filing: Announcement made through the London Stock Exchange’s regulatory information service.
- Other Actions: No other corporate actions involving Circle8 Group Inc. were noted on the date of this update.
Related Stock Performance (Last 24 h)
| Ticker | 24‑h Change | Current Price (USD) | Market Capitalisation (USD mn) |
|---|---|---|---|
| SYPR (Sypris) | 0 % | 1.78 | 40.8 |
| SPWH (Sportsman’s Warehouse Holdings) | –0.95 % | 1.05 | 41.1 |
| JETBF (Global Crossing Airlines Group) | 0 % | 0.61 | 41.3 |
| CELU (Celularity) | –7.2 % | 1.26 | 40.6 |
| 9HA.F (Elicio Therapeutics) | –12.36 % | 1.56 | 41.0 |
KRAS Inhibitor Market Context
Elicio Therapeutics, listed as 9HA.F, is active in the KRAS inhibitor market. Key points:
- Market Drivers: Rising prevalence of KRAS‑mutated cancers and a robust pipeline of next‑generation agents.
- Competitive Landscape: Companies such as Eli Lilly, Merck, Roche, and ELICIO Therapeutics are advancing treatments targeting G12C and emerging subtypes (e.g., G12D).
- Regulatory Milestones: Several candidates have received breakthrough designations, accelerating approval pathways.
- Geographic Focus: United States, European Union, United Kingdom, and Japan.
- Key Indications: Non‑small‑cell lung cancer, colorectal cancer, pancreatic cancer, and ovarian cancer.
- Projected Growth: The market is expected to expand over the next decade, potentially reshaping standard care practices as clinical developments progress.
Company Profile – Circle
Circle (CIRC) is listed on the OTC Bulletin Board, a secondary market for publicly traded securities in the United States. The company’s shares are traded on multiple exchanges, with the current trading price around USD 0.38.
This article provides factual information regarding Circle’s recent market performance, corporate actions, and related market context. No speculative content is included.
